A Trial of Firesorb in Patients With Coronary Artery Disease: FUTURE-II

NCT ID: NCT02890160

Last Updated: 2023-10-25

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 430 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-08-24
• Study Completion Date: 2024-10-31

Brief Summary

The FUTURE-II study is a confirmative clinical trial for Sirolimus Target Eluting Bioresorbable Vascular Scaffold (Firesorb) after the feasibility and safety of the device has been preliminary confirmed in a small-scale First-in-Man clinical trial.

Detailed Description

This study is a prospective, multicenter, single-blind, randomized controlled trial in patients with coronary artery disease caused by up to two de novo native coronary artery lesions in separate epicardial vessels. The goal is to evaluate the safety and effectiveness of Firesorb to support the approval of the Chinese Food and Drug Administration (CFDA) for this product. The Abbott's XIENCE Everolimus-eluting Coronary Stent System is selected as the control device. 430 subjects will be recruited. All subjects will be 1:1 randomly assigned to experimental group and control group. All subjects will undergo clinical follow-up at 1-month, 6-month, 1-year, 2-year, 3-year, 4-year and 5-year post-index procedure. All subjects will undergo angiographic follow-up at 1-year post-index procedure; of which 3-5 centers will be specified as a subgroup to complete OCT follow-up (n=80, 40 each in test and control group).

Conditions

Coronary Artery Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Firesorb

Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）

Group Type: EXPERIMENTAL

Firesorb

Intervention Type: DEVICE

Sirolimus Target Eluting Bioresorbable Vascular Scaffold

XIENCE

Implantation of the XIENCE Everolimus Eluting Coronary Stent System

Group Type: ACTIVE_COMPARATOR

XIENCE

Intervention Type: DEVICE

Everolimus Eluting Coronary Stent System

Interventions

Firesorb

Sirolimus Target Eluting Bioresorbable Vascular Scaffold

Intervention Type: DEVICE

XIENCE

Everolimus Eluting Coronary Stent System

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. 18-75 years of age, males or non-pregnant females;

2. With silent ischemia evidence, patients with stable or unstable angina, or in patients with old myocardial infarction;

3. Patients with indications for coronary artery bypass graft surgery;

4. To understand the purpose of testing, voluntary and informed consent, patients undergoing invasive imaging follow-up.

1. One or two de novo target lesions:

1. If there is one target lesion, a second non-target lesion may be treated but the non-target lesion must be present in a different epicardial vessel, and must be treated first with a successful, uncomplicated result prior to randomization of the target lesion.

2. If two target lesions are present, they must be present in different epicardial vessels and both must satisfy the angiographic eligibility criteria.

3. The definition of epicardial vessels means the LAD, LCX and RCA and their branches. Thus, the patient must not have lesions requiring treatment in e.g. both the LAD and a diagonal branch.

2. Target lesion(s) must be located in a native coronary artery with a visually estimated or quantitatively assessed % diameter stenosis (DS) of ≥ 50% and < 100% with a thrombolysis in myocardial infarction (TIMI) flow of ≥1 and one of the following: stenosis ≥ 70%, an abnormal functional test (e.g. fractional flow reserve, stress test), unstable angina or post-infarct angina. Lesion(s) must be located in a native coronary artery with RVD by visual estimation of ≥ 2.5 mm and ≤4.0 mm. Lesion(s) must be located in a native coronary artery with length by visual estimation of ≤ 25 mm.

3. Each target lesion may be covered with one stent.

Exclusion Criteria

1. Within 1 week of any acute myocardial infarction or myocardial enzymes did not return to normal;

2. Implantation of stent in target vessel within 1 year , patients with planned intervention again within six months;

3. Severe congestive heart failure (NYHA III and above) ,or left ventricular ejection fraction <40% (ultrasound or left ventricular angiography);

4. Preoperative renal function serum creatinine >2.0mg/DL; receiving hemodialysis;

5. Bleeding, active gastrointestinal ulcers, brain hemorrhage or subarachnoid hemorrhage and half year history of ischemic stroke, antiplatelet agents and would not allow an anticoagulant therapy contraindications patients undergoing antithrombotic therapy;

6. Aspirin, clopidogrel, heparin, contrast agent, poly lactic acid polymer and rapamycin allergies;

7. The patient's life expectancy is less than 12 months;

8. Top participated in other drug or medical device and does not meet the primary study endpoint in clinical trials time frame;

9. Researchers determine patient compliance is poor, unable to complete the study in accordance with the requirements;

10. Heart transplantation patients;

11. The unstable arrhythmia, such as high risk ventricular extrasystole and ventricular tachycardia;

12. Cancer need chemotherapy;

13. Immunosuppression and autoimmune diseases, planned or undergoing immunosuppressive therapy;

14. Planning or being receiving long-term anticoagulant therapy, such as heparin, warfarin, etc;

15. Within six months for elective surgery requires stopping aspirin, Clopidogrel patients;

16. Blood test prompted platelet counts of less than 100x10E9/L or greater than 700x10E9/L, white blood cells than 3x10E9/L; known or suspected liver disease (such as hepatitis);

17. Peripheral vascular disease, 6F catheter is not available.

1. left main coronary artery disease;

2. severe triple vessel lesion and required revascularization.

1. Aorto-ostial right coronary artery (RCA) lesion (within 3 mm of the ostium).

2. Lesion located within 3 mm of the origin of the Left Anterior Descending Artery (LAD) or left circumflex artery (LCX).

3. Lesion involving a bifurcation with a:

1. side branch ≥ 2.5 mm in diameter, or

2. side branch with diameter stenosis ≥ 50%, or

3. side branch requiring guide wire, or

4. side branch requiring dilatation.

4. Anatomy proximal to or within the lesion that may impair delivery of Firesorb or XIENCE stent:

1. Extreme angulation (≥ 90°) proximal to or within the target lesion.

2. Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion.

3. Moderate or heavy calcification proximal to or within the target lesion.

5. Lesion or vessel involves a myocardial bridge.

6. Vessel contains thrombus as indicated in the angiographic images or by IVUS or OCT.

7. Vessel has been previously treated with a stent at any time prior to the index procedure such that the Firesorb or XIENCE would need to cross the stent to reach the target lesion.

8. Vessel has been previously treated and the target lesion is within 5 mm proximal or distal to a previously treated lesion.

9. Lesion which prevents successful balloon pre-dilatation, defined as full balloon expansion with the following outcomes:

1. Residual %DS is a maximum of < 40% (per visual estimation), ≤ 20% is strongly recommended.

2. TIMI Grade-3 flow (per visual estimation).

3. No angiographic complications (e.g. distal embolization, side branch closure).

4. No dissections National Heart Lung and Blood Institute (NHLBI) grade D-F.

5. No chest pain lasting > 5 minutes.

6. No ST depression or elevation lasting > 5 minutes.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai MicroPort Medical (Group) Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Runlin Gao, MD

Role: PRINCIPAL_INVESTIGATOR

Fu Wai Hospital & National Center for Cardiovascular Diseases in China

Locations

Fu Wai Hospital

Beijing, Beijing Municipality, China

Countries

China

References

Jiang J, Li C, Chen D, Song L, Cui Z, Li P, Gan L, Chen Y, Li H, Jia S, He S, Lu W, Gao R, Wang J; FUTURE III Investigators. Firesorb bioresorbable scaffold for de novo coronary artery disease: 1-year clinical outcomes. BMC Med. 2025 Jul 9;23(1):419. doi: 10.1186/s12916-025-04254-0.

Reference Type: DERIVED

PMID: 40629329 (View on PubMed)

Song L, Xu B, Chen Y, Zhou Y, Jia S, Zhong Z, Su X, Ma Y, Zhang Q, Liu J, Wang Y, Guan C, Zheng M, Qiao S, Gao R; FUTURE-II Trial Investigators. Thinner Strut Sirolimus-Eluting BRS Versus EES in Patients With Coronary Artery Disease: FUTURE-II Trial. JACC Cardiovasc Interv. 2021 Jul 12;14(13):1450-1462. doi: 10.1016/j.jcin.2021.04.048. Epub 2021 May 18.

Reference Type: DERIVED

PMID: 34238555 (View on PubMed)

Other Identifiers

MicroPort_Firesorb_RCT

Identifier Type: -

Identifier Source: org_study_id